Ecofibre has announced the termination of chief science officer and EOF-Bio chief operating officer Dr Alex Capano’s employment effective immediately.
Earlier this month the firm said it would “vigorously defend” legal action lodged by Capano over allegations that senior executives looked out for themselves and the parent company at the expense of its EOF-Bio subsidiary.
Capano filed proceedings in Delaware in the US accusing several board directors of being “conflicted” in their roles with the company.
Ecofibre formed EOF-Bio in mid-2023 to commercialise patents for the treatment of endometriosis and ovarian cancer co-developed by Ecofibre and the University of Newcastle. It was led by Capano, who had spent the previous five years as the company’s chief science officer.
Court documents allege she was placed on “administrative leave” earlier this year shortly after “all EOF employees except Capano were fired”.
Ecofibre announced her departure to the ASX this morning.
